OAM
ATHE

Oxford Asset Management’s Alterity Therapeutics ATHE Stock Holding History

Oxford Asset Management’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,361
Closed -$136K – 664
2014
Q4 		$136K Buy
+1,361
New +$147K ﹤0.01% 638

Other funds holding ATHE

GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $525M AUM 21.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return
NCCM
Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Oxford Asset Management's ATHE Position: Q1 2015 in Review

Oxford Asset Management sold out of Alterity Therapeutics (ATHE) in Q1 2015, closing a stake of 1,361 shares — an estimated $136K sold.

Oxford Asset Management first reported a position in ATHE in Q4 2014 and held it in 1 quarter. The position peaked at $136K in Q4 2014. 21 funds tracked by Wall St. Rank hold ATHE as of Q1 2015.

  • Oxford Asset Management reported no remaining Alterity Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Oxford Asset Management sold 1,361 Alterity Therapeutics shares in Q1 2015, an estimated $136K.
  • Oxford Asset Management first reported a position in Alterity Therapeutics in Q4 2014 and held it in 1 quarter.
  • Oxford Asset Management's Alterity Therapeutics position peaked at $136K in Q4 2014.
  • 21 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2015.

Based on Oxford Asset Management's 13F filing for Q1 2015, filed 15 Apr 2015.